FDA approves subcutaneous isatuximab-irfc for multiple myeloma indications, offering an efficient delivery alternative to intravenous administration. The US Food and Drug Administration (FDA) has ...
Subcutaneous isatuximab is now approved with pomalidomide/dexamethasone, carfilzomib/dexamethasone, and bortezomib/lenalidomide/dexamethasone, aligning SC ...
An engineered stem cell therapy reversed new-onset Type 1 diabetes in mice by shifting the immune system away from attacking ...
One of South Carolina’s top providers of MSC injections opens a new clinic to offer services to more patients in the area. MOUNT PLEASANT, SC, UNITED STATES, June ...
Subcutaneous anifrolumab 120mg weekly demonstrated a statistically significant and clinically meaningful reduction in SLE disease activity (58.5% BICLA response vs 43.2% for placebo) with a safety ...
Credit: AstraZeneca. The new weekly 120 mg SC formulation, supported by TULIP-SC trial results, offers patients with moderate to severe SLE a self-administered alternative to monthly IV infusions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results